Mediscor
Workshop Presentation
11 August 2010
Mediscor Workshop Presentation 11 August 2010 Content 1. Profile - - PowerPoint PPT Presentation
Mediscor Workshop Presentation 11 August 2010 Content 1. Profile overview 2. Our services 3. Unique capabilities 4. Conclusions Presented by: Christo Rademan - Managing Director Mediscor Profile Overview An organisation specialising
11 August 2010
Presented by:
Christo Rademan - Managing Director
Integrated Utilisation Management & Pharmaceutical Care
Pharmacy Claims Patient Claims Clinic/Doctor Claims Hospital TTO Claims
Central Patient Medicine Record (History) at Active Ingredient Level
Clinical Information
Each category can be expanded to accommodate specific requirements such as capitation, formularies and management of virtual networks (on either a positive or negative basis)
all” approach
Claim field format checks Provider validation checks Member validation checks Verify dependant code Waiting period check Duplicate check
Examples:
Refill limits e.g. 12 fills per year for chronic medication Drug to age range limitations e.g. Ritalin™ and generics will pay for patients 16 years and younger Fill limitations per period e.g. 1 fill per 26 days Drug to gender limitations e.g. HRT females Product quantity limits e.g. 200 analgaesics/365 days Invalid prescriber speciality e.g. Diane™ – Dermatologist Products requiring pre-auth e.g. Revelex™ Broad category exclusions e.g. soaps/shampoos excluded Patient specific exclusions e.g. for pre-existing conditions and general waiting periods Specific products excluded e.g. Urinary antiseptics Pre-existing conditions Patient specific as advised by scheme Waiting periods Patient specific as advised by scheme
Utilisation is checked against patient history at active ingredient level
Ingredient duplication e.g. Stopayne™/Stilpane™ Drug to age interaction e.g. Ciprobay™ under 18 years Maximum daily dose exceeded Drug to gender interaction e.g. Proscar™ Therapeutic duplication e.g. Zantac™/Tagamet™ Drug to disease interaction e.g. Inderal™ Asthma Drug to drug interaction e.g. Sporanox™/Fendin™ Drug to inferred health state Drug to allergy – In development
All edits are flexible and can be set as reject, informational or report
This is a financial rule not a clinical decision
switch-out to the scheme
supplied on the daily cardholder file
Product Paid status Benefit indicator Decision
Ventolin (Asthma) P L=PMB Auto Lists Fosamax (Osteoporosis) P M=Chronic Pre-authorisation Panado (Analgesic) P F=Savings Benefit rules Amoxil (Antibiotic) P T=Acute Benefit rules Inteflora (Supplement) R Benefit rules Providers are provided with a clear free-text message on all rejections.
2002: Chronic Medication Management – Gold Award 2003: Chronic Medication Management – Diamond Award 2004: Medicine Utilization Management – Diamond Award Technology Services & Electronic Medicine Management – Diamond Award 2005: Technology Services & Electronic Medicine Management – Diamond Award 2006: Technology Services & Electronic Medicine Management – Gold Award Chronic Medication Management – Gold Award 2008: Chronic Medication Management - Diamond Arrow Award 2009: Technology Services & Electronic Medicine Management – Golden Arrow Award Chronic Medication Management – Diamond Arrow Award
medicine expenditure results, industry comparison and profiling
(where ChroniLine™ service is performed)
reference used by private and public healthcare
Providers SWITCH Mediscor PBM SWITCH Mediscor PBM
Scheme / Administrator
Supported by:
lives in other countries
developments/enhancements that other users initiate
changes
flexible solutions
Service Category Value 2009 Value 2008 Claims Processing:
Utilisation management 378,505,426 267,806,333 Clinical management 65,474,715 55,577,311 Pricing management 126,327,487 111,082,707 Reference price 113,646,496 79,868,485
ChroniLine™
13,222,407 8,595,912
TOTAL 697,176,531 522,930,748 Multiple of fees paid 8.7x 6.9x
Our flexible, open business culture is focused on building successful clients